PTCT (PTC Therapeutics Corp) Net earnings per share (EPS TTM)

PTC Therapeutics Corp (PTCT) - corporate logo

PTC Therapeutics, Inc. (PTCT) is optimizing drug production through partnerships with external research centers. The year-over-year EPS (TTM) history demonstrates profit dynamics, where the indicator value reaches -113.80. High brand authority in neurology guarantees patient loyalty, while the specifics of orphan drugs ensure colossal margins during production scaling, creating significant investment potential.

PTC Therapeutics Corp - PTCT Earnings per share for the last twelve months (period 02/11/2024 - 11/18/2026)

PTCT (PTC Therapeutics Inc): analytical breakdowns and indicator data

- price and consensus price forecast:
- business market valuation indicators:
Fundamental company valuation:PTCT PTC Therapeutics Corp
Flagship merchandise of PTC Therapeutics

Profit dynamics are critical for orphan drug developer PTC Therapeutics, Inc. (PTCT), as patent protection and subsidies determine the period of monopoly profit extraction. The current annual EPS TTM growth rate reflects the change in net income per share over the last 12 months relative to the previous year, allowing for the identification of fundamental risks regarding overpayment or asset undervaluation prior to the release of official financial statements.

Direct competitors

Net earnings per one share for the last twelve months Jazz Pharma|CYTK (Cytokinetics Inc.) - Net earnings per share for the last 12 months|Scholar Rock Inc. (SRRK) - Net earnings per share (EPS TTM)|Earnings per share for the last twelve months Centessa Pharmaceuticals|Net earnings per one share for the last twelve months dyne-tx.com DYN|Earnings per share for the last twelve months Edgewise Corp (EWTX)|RAPP - Net earnings per one share for the last twelve months|Earnings per share for the last twelve months Alumis Corp ALMS|Zevra Corp - Earnings per share for the last twelve months|CTNM - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Larimar Therapeutics|CAPR: Net earnings per share (EPS TTM)|Net earnings per share for the trailing year Entrada TRDA|Net earnings per share for the last 12 months PTHS|Net earnings per one share for the last twelve months medicinova.com MNOV|Net earnings per share (EPS TTM) SER|Earnings per share for the last twelve months BTAI (BioXcel Therapeutics)|Earnings per share for the last twelve months ProMIS Neurosciences, Inc. PMN|APUS (Apimeds) - Earnings per one share for the last 12 months|AEON - Earnings per share for the last twelve months|Net earnings per share for the last four quarters NLS Pharmaceutics Ltd. NLSP|Bionomics Limited (BNOX) - Earnings per share for the last twelve months|fsdpharma.com - Earnings per share for the trailing year|RETA (reatapharma.com) - Net earnings per share (EPS TTM)